Literature DB >> 18300338

Role of symptoms in diagnosis and outcome of gastric cancer.

Giovanni Maconi, Gianpiero Manes, Gabriele-Bianchi Porro.   

Abstract

Gastric cancer is one of the most common cancers and the second most common cause of cancer deaths worldwide. Apart from Japan, where screening programmes have resulted in early diagnosis in asymptomatic patients, in most countries the diagnosis of gastric cancers is invariably made on account on dyspeptic and alarm symptoms, which may also be of prognostic significance when reported by the patient at diagnosis. However, their use as selection criteria for endoscopy seems to be inconsistent since alarm symptoms are not sufficiently sensitive to detect malignancies. In fact, the overall prevalence of these symptoms in dyspeptic patients is high, while the prevalence of gastro-intestinal cancer is very low. Moreover, symptoms of early stage cancer may be indistinguishable from those of benign dyspepsia, while the presence of alarm symptoms may imply an advanced and often inoperable disease. The features of dyspeptic and alarm symptoms may reflect the pathology of the tumour and be of prognostic value in suggesting site, stage and aggressiveness of cancer. Alarm symptoms in gastric cancer are independently related to survival and an increased number, as well as specific alarm symptoms, are closely correlated to the risk of death. Dysphagia, weight loss and a palpable abdominal mass appear to be major independent prognostic factors in gastric cancer, while gastro-intestinal bleeding, vomiting and also duration of symptoms, do not seem to have a relevant prognostic impact on survival in gastric cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18300338      PMCID: PMC2690660          DOI: 10.3748/wjg.14.1149

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  70 in total

1.  Does endoscopy diagnose early gastrointestinal cancer in patients with uncomplicated dyspepsia?

Authors:  N Sundar; V Muraleedharan; J Pandit; J T Green; R Crimmins; G L Swift
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

2.  Missing gastric cancer in dyspepsia.

Authors:  N Schmidt; U Peitz; H Lippert; P Malfertheiner
Journal:  Aliment Pharmacol Ther       Date:  2005-04-01       Impact factor: 8.171

3.  Combination of age and sex improves the ability to predict upper gastrointestinal malignancy in patients with uncomplicated dyspepsia: a prospective multicentre database study.

Authors:  Riccardo Marmo; Gianluca Rotondano; Roberto Piscopo; Maria Antonia Bianco; Paola Russo; Paola Capobianco; Livio Cipolletta
Journal:  Am J Gastroenterol       Date:  2005-04       Impact factor: 10.864

4.  Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked.

Authors:  D J Bowrey; S M Griffin; J Wayman; D Karat; N Hayes; S A Raimes
Journal:  Surg Endosc       Date:  2006-10-05       Impact factor: 4.584

5.  Meta-analysis: the diagnostic value of alarm symptoms for upper gastrointestinal malignancy.

Authors:  G A J Fransen; M J R Janssen; J W M Muris; R J F Laheij; J B M J Jansen
Journal:  Aliment Pharmacol Ther       Date:  2004-11-15       Impact factor: 8.171

6.  Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

Authors:  H J Andreyev; A R Norman; J Oates; D Cunningham
Journal:  Eur J Cancer       Date:  1998-03       Impact factor: 9.162

7.  Norwegian multicentre study of survival and prognostic factors in patients undergoing curative resection for gastric carcinoma. The Norwegian Stomach Cancer Trial.

Authors:  T K Haugstvedt; A Viste; G E Eide; O Söreide
Journal:  Br J Surg       Date:  1993-04       Impact factor: 6.939

8.  Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome.

Authors:  S J Panter; H O'Flanagan; M G Bramble; A P S Hungin
Journal:  Aliment Pharmacol Ther       Date:  2004-05-01       Impact factor: 8.171

9.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

Review 10.  Prognostic factors for gastric cancer influencing clinical practice.

Authors:  J D Harrison; J W Fielding
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

View more
  56 in total

1.  Clinically significant endoscopic findings in a multi-ethnic population with uninvestigated dyspepsia.

Authors:  Sanjiv Mahadeva; Khean-Lee Goh
Journal:  Dig Dis Sci       Date:  2012-06-12       Impact factor: 3.199

2.  Inappropriate prescribing of proton pump inhibitors in older patients: effects of an educational strategy.

Authors:  Hanifat Hamzat; Hao Sun; Joanna C Ford; Joan Macleod; Roy L Soiza; Arduino A Mangoni
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

3.  Multiple metabolic parameters and visual assessment of 18F-FDG uptake heterogeneity of PET/CT in advanced gastric cancer and primary gastric lymphoma.

Authors:  Yixuan Ren; Juan Liu; Ling Wang; Yongjun Luo; Xiaofang Ding; Aiqi Shi; Jiangyan Liu
Journal:  Abdom Radiol (NY)       Date:  2020-11

4.  Impact of lifestyle factors and nutrients intake on occurrence of gastrointestinal cancer in Tunisian population.

Authors:  Olfa Baroudi; Arij Ben Chaaben; Amel Mezlini; Amel Moussa; Ines Omrane; Irene Jilson; Amel Benammar-Elgaaied; Soufia Chabchoub
Journal:  Tumour Biol       Date:  2014-03-11

5.  Effect of doxorubicin, oxaliplatin, and methotrexate administration on the transcriptional activity of BCL-2 family gene members in stomach cancer cells.

Authors:  Dimitra Florou; Christos Patsis; Alexandros Ardavanis; Andreas Scorilas
Journal:  Cancer Biol Ther       Date:  2013-05-10       Impact factor: 4.742

Review 6.  Saliva diagnostics - Current views and directions.

Authors:  Karolina Elżbieta Kaczor-Urbanowicz; Carmen Martin Carreras-Presas; Katri Aro; Michael Tu; Franklin Garcia-Godoy; David Tw Wong
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-08

7.  Gastric low-grade mucosal-associated lymphoid tissue-lymphoma: Helicobacter pylori and beyond.

Authors:  Angelo Zullo; Cesare Hassan; Francesca Cristofari; Francesco Perri; Sergio Morini
Journal:  World J Gastrointest Oncol       Date:  2010-04-15

8.  Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.

Authors:  Chen Xie; Vinod Vijay Subhash; Arpita Datta; Natalia Liem; Shi Hui Tan; Mei Shi Yeo; Woei Loon Tan; Vivien Koh; Fui Leng Yan; Foong Ying Wong; Wai Keong Wong; Jimmy So; Iain Beehuat Tan; Nisha Padmanabhan; Celestial T Yap; Patrick Tan; Liang Kee Goh; Wei Peng Yong
Journal:  Cell Oncol (Dordr)       Date:  2016-02-11       Impact factor: 6.730

9.  Platelet Distribution Width as a Predictor of Metastasis in Gastric Cancer Patients.

Authors:  Meral Gunaldi; Dilek Erdem; Sema Goksu; Seyda Gunduz; Yildiz Okuturlar; Eda Tiken; Huseyin Aksoy; Mustafa Yildirim
Journal:  J Gastrointest Cancer       Date:  2017-12

10.  Incidence and survival of stomach cancer in a high-risk population of Chile.

Authors:  Katy Heise; Enriqueta Bertran; Marcelo E Andia; Catterina Ferreccio
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.